24. Spontaneous Breathing Trial Technique — Pressure Support vs. T-Piece

Quick Recap

Cross-cutting protocol — companion to Post-Extubation Failure & Reintubation and Early vs. Late Tracheostomy Timing protocols. Addresses the specific technique used to conduct a spontaneous breathing trial (SBT) — pressure support ventilation vs. T-piece — grounded in a large, practice-influencing single-center-network trial with a striking mortality finding, complicated by a specific, acknowledged co-intervention imbalance and a pooled meta-analysis across 10 RCTs that does not confirm the extubation-rate benefit at a population level.

1. Definition

Spontaneous breathing trial (SBT): the standard method for assessing readiness for extubation in mechanically ventilated patients, involving a defined period of unassisted or minimally-assisted breathing to evaluate the patient's ability to sustain adequate ventilation and oxygenation off full ventilatory support.

T-piece SBT: disconnection from the ventilator circuit entirely, breathing through a T-shaped adapter with supplemental oxygen but no positive pressure support — the more physiologically demanding of the two approaches, requiring the patient to overcome the full resistance of the endotracheal tube unassisted.

Pressure support ventilation (PSV) SBT: remaining connected to the ventilator with a modest level of inspiratory pressure support (commonly 5–8 cmH2O) — specifically intended to offset the resistive work imposed by the endotracheal tube itself, making this the less physiologically demanding approach.

The specific trial comparison that has most shaped recent practice: 30 minutes of PSV vs. 2 hours of T-piece — note that the two major approaches compared in the most influential recent trial differ in both technique and duration simultaneously, a design choice with direct interpretive implications (Section 11).

2. Pathophysiology

The endotracheal tube itself imposes a measurable, physiologically meaningful resistive workload that does not exist once the tube is removed — meaning a T-piece SBT, precisely because it withholds pressure support, may systematically overestimate the true post-extubation work of breathing the patient will actually face, since the tube's resistance is a temporary artifact of the assessment itself, not a permanent feature of the patient's post-extubation physiology. This is the core physiological rationale for pressure support during SBT: PSV is proposed to more accurately simulate the patient's true, tube-independent readiness for unassisted breathing than an unassisted T-piece trial, which conflates the patient's genuine respiratory reserve with the artificial burden of breathing through a narrow endotracheal tube.

3. Immediate Stabilization (ABCDE) — SBT Technique as Part of Ventilator Liberation

Not a standalone stabilization scenario; SBT technique selection sits within the broader ventilator liberation process (cross-reference Post-Extubation Failure & Reintubation protocol):

Checklist:

4. Focused History

• Duration of mechanical ventilation and reason for ventilatory support
• Risk factors for extubation failure/reintubation (cross-reference Post-Extubation Failure & Reintubation protocol for the full risk-stratification framework)
• Comorbidities relevant to respiratory reserve (COPD, chronic respiratory failure)

5. Comprehensive System-wise Examination

• Respiratory: standard readiness-for-weaning assessment (oxygenation, ventilatory parameters, secretion burden, mental status) per standard extubation-readiness criteria — not distinct to the SBT-technique question specifically

6. Syndrome Identification — Reframed as SBT-Technique Applicability Classification

• General ICU population meeting standard weaning-readiness criteria: the population studied in the major trial — evidence for PSV over T-piece is genuinely more complex than a simple "PSV is better" summary suggests (Section 11)
• High risk of reintubation specifically: post hoc analysis found PSV independently associated with successful extubation in this specific, higher-risk population, without an increased reintubation signal — though the authors of this specific analysis explicitly called for confirmatory prospective evidence before broader application
• COPD-specific weaning: a separate, dedicated RCT (Santos Pellegrini et al.) has examined PSV vs. T-piece specifically in this population, reflecting recognition that COPD's distinct respiratory mechanics may warrant separate consideration from the general ICU weaning population

7. Differential Diagnosis — Not Applicable

Cross-reference Post-Extubation Failure & Reintubation protocol for the differential diagnosis of extubation failure itself; this protocol addresses the SBT technique decision preceding that assessment.

8. Severity/Risk Assessment

Cross-reference Post-Extubation Failure & Reintubation protocol's risk-stratification framework (MACOCHA-adjacent and other risk criteria for extubation failure); this protocol's specific contribution is the SBT-technique decision that precedes and informs, but does not replace, that broader risk assessment.

9. Investigations — Not a Primary Diagnostic Workup

10. Point-of-Care Ultrasound — Not a Primary Component

11. Evidence-Based Management — A Large, Influential Trial With a Genuine, Acknowledged Confound

Subirà et al. (2019) — The Largest, Most Influential Recent Trial

• Subirà et al., JAMA 2019: a large multicenter RCT across 18 Spanish ICUs, n=1,153, comparing a 30-minute PSV (8 cmH2O) SBT vs. a 2-hour T-piece SBT in adults deemed ready for weaning after ≥24 hours of mechanical ventilation
• Primary outcome (successful extubation, no reintubation within 72 hours): 82.3% (PSV) vs. 74.0% (T-piece), absolute difference 8.2% (95% CI 3.4–13.0%), p=0.001 — a substantial, statistically significant, clinically meaningful difference favoring the shorter, less demanding PSV strategy
• Reintubation among successfully extubated patients: no significant difference (11.1% vs. 11.9%, p=0.63) — the PSV group's higher overall successful-extubation rate was not offset by a correspondingly higher failure rate among those who were extubated, an important, reassuring pattern
• A genuinely striking secondary finding: hospital mortality significantly lower in the PSV group (10.4% vs. 14.9%, p=0.02), and 90-day mortality also significantly lower (13.2% vs. 17.3%, hazard ratio 0.74, 95% CI 0.55–0.99) — a real, statistically significant mortality difference from what is, on its face, simply a difference in how a 30-minute-to-2-hour assessment is conducted, a genuinely large effect for what might intuitively seem like a modest, procedural choice

The Specific, Directly Acknowledged Methodological Confound

• A specific, important co-intervention imbalance: the trial's own design allowed attending physicians to decide on post-extubation respiratory support strategy, and physicians were not blinded to SBT allocation — resulting in significantly more patients in the PSV group receiving prophylactic high-flow nasal oxygen or NIV after extubation (24.7–25% vs. 18.7–19%, p=0.01) — independent commentary specifically flagged this as an imbalance "which may have affected the results" and "could have skewed results favoring the PSV 30-minute SBT"
• Why this matters: prophylactic post-extubation NIV/HFNC has its own separately established evidence base for reducing extubation failure and improving outcomes in at-risk patients (cross-reference Post-Extubation Failure & Reintubation and HFNC vs. NIV in Acute Hypoxemic Respiratory Failure protocols) — meaning some portion of the PSV group's superior outcomes may be attributable to this co-intervention imbalance rather than to the SBT technique itself, a genuine, unresolved confound the trial's own open-label, physician-directed design could not fully control for
• A second, related design consideration: the trial compared 30 minutes of PSV against 2 hours of T-piece — simultaneously varying both technique and duration — meaning the observed difference cannot be cleanly attributed to pressure support alone versus the shorter overall duration itself; independent commentary specifically noted this dual-variable design "might explain the higher percentage of patients who had a successful initial spontaneous-breathing trial...in the PSV group" as much as the pressure-support technique specifically

The Pooled Meta-Analytic Picture — A More Tempered Conclusion

• A systematic review and meta-analysis of 10 RCTs, n=3,165 (predating full incorporation of some more recent trials): found no significant difference in successful extubation rate between T-piece and PSV groups overall (OR 0.91, 95% CI 0.78–1.07, p=0.27, with substantial heterogeneity, I²=79%) — a genuinely important, more tempered pooled conclusion that does not confirm Subirà's dramatic single-trial finding at the level of the broader accumulated evidence base
• High between-study heterogeneity (I²=79%) itself signals that the pooled trials are not straightforwardly comparable — likely reflecting exactly the kind of duration/technique conflation, co-intervention variability, and population differences (general ICU vs. high-risk-for-reintubation vs. COPD-specific) that complicate simple synthesis across this literature

High-Risk-for-Reintubation Population — A More Consistent, Though Still Preliminary, Signal

• Post hoc analysis of a separate multicenter trial focusing specifically on patients at high risk of extubation failure: PSV-based initial SBT was associated with a higher proportion of successful extubation (77% vs. 63%, p=0.0002) without a significantly different reintubation rate (13% vs. 10%, p=0.43), and PSV was independently associated with successful extubation on adjusted analysis (adjusted OR 1.60, 95% CI 1.30–2.18) — the study's own authors explicitly stated that "another large prospective RCT is needed to confirm these findings in this population...before being in a position to apply this" broadly, an appropriately cautious conclusion given the post hoc, non-randomized-by-SBT-technique nature of this specific analysis

Practical Synthesis

Subirà et al. represents a large, influential, well-conducted trial with a genuinely striking mortality finding — but this protocol treats that finding with appropriate calibration given the specific, directly acknowledged co-intervention imbalance (differential post-extubation NIV/HFNC use) and the dual-variable (technique-plus-duration) trial design, both of which complicate clean attribution of the mortality benefit to pressure support technique alone. The broader pooled meta-analytic evidence (10 RCTs, substantial heterogeneity) does not confirm a significant extubation-rate benefit for PSV over T-piece at the population level, a genuinely important tempering consideration against over-interpreting Subirà's single-trial result as the definitive final answer. A shorter (30-minute), pressure-support-assisted SBT is a reasonable, evidence-informed default for most patients, given its lower demand on the patient and the absence of an increased reintubation signal in the major supporting trial — but clinicians should specifically ensure that prophylactic post-extubation respiratory support (NIV/HFNC) is applied consistently based on established, independent risk criteria (cross-reference Post-Extubation Failure & Reintubation and HFNC vs. NIV in Acute Hypoxemic Respiratory Failure protocols) regardless of which SBT technique is chosen, rather than allowing this co-intervention to vary unsystematically alongside the SBT-technique decision as it did in the pivotal trial. For patients at high risk of extubation failure specifically, a more individualized approach, potentially favoring PSV based on the promising though not yet definitively confirmed post hoc signal, may be reasonable pending further dedicated confirmatory trials.

12. Organ Support

Directly interacts with Post-Extubation Failure & Reintubation and HFNC vs. NIV in Acute Hypoxemic Respiratory Failure protocols — the post-extubation respiratory support decision should be made consistently and independently of the SBT technique decision, given the specific confound identified in Section 11.

13. Disease-Specific Therapy — Not Applicable

This is a ventilator-mode/procedural-technique protocol rather than a pharmacotherapy one.

14. Consultation Matrix

15. Monitoring Framework

• Clinical: standard SBT tolerance monitoring (respiratory rate, work of breathing, oxygenation, hemodynamic stability) regardless of technique chosen
• Post-extubation: consistent application of prophylactic respiratory support per established risk criteria, independent of SBT technique used (Section 11)

16. ICU Bundle Checklist

17. Complications — Not a Primary Component

Cross-reference Post-Extubation Failure & Reintubation protocol for the complication profile of extubation failure/reintubation itself, which this SBT-technique decision aims to minimize.

18. Escalation & De-escalation — Not Directly Applicable

Cross-reference Post-Extubation Failure & Reintubation protocol for the relevant escalation framework if extubation failure occurs regardless of SBT technique chosen.

19. ICU Discharge Criteria — Not Directly Applicable

20. Documentation & Medicolegal Checklist

• SBT technique and duration used documented
• Post-extubation respiratory support plan documented, with rationale independent of SBT technique choice
• SBT tolerance and outcome documented

21. Key Guidelines

• 2017 ATS/CHEST guideline (predating Subirà's 2019 trial, based on meta-analysis of 3 RCTs available at the time): suggested initial SBT be conducted with modest inspiratory pressure augmentation rather than T-piece or CPAP — current guidance may not fully reflect the more complex picture that has emerged from Subirà's trial alongside the pooled meta-analytic evidence discussed above, and clinicians should be aware this specific guideline recommendation predates some of the more recent, complicating evidence

22. Landmark Trials

23. Controversies

• The specific co-intervention confound in Subirà's trial deserves more weight than a brief methods-section caveat: differential prophylactic post-extubation NIV/HFNC use between arms (24.7–25% vs. 18.7–19%) is not a minor imbalance given that this specific intervention has its own separately established efficacy for reducing extubation failure — this protocol treats this as a genuine, potentially substantial contributor to the observed mortality difference, not simply a footnote, consistent with this library's general practice of engaging honestly with acknowledged confounds rather than presenting dramatic single-trial findings without their attached caveats.
• The tension between a single large, influential positive trial and a pooled meta-analysis that does not confirm the same effect is structurally similar to several other examples in this library (cross-reference the general pattern discussed across multiple protocols regarding single-trial vs. pooled-evidence interpretation) — the appropriate response is neither to dismiss Subirà's trial nor to treat it as having definitively settled the question, but to recognize genuine, still-unresolved uncertainty about how much of the observed benefit reflects the SBT technique itself versus the co-intervention and design confounds specifically identified.
• Guideline lag: the 2017 ATS/CHEST guideline predates Subirà's trial and the subsequent, more complicating meta-analytic evidence — clinicians should be aware that formal guideline language may not yet fully reflect the genuine complexity that has emerged in this specific literature since 2019.

24. References

1. Subirà C, Hernández G, Vázquez A, et al. Effect of pressure support vs T-piece ventilation strategies during spontaneous breathing trials on successful extubation among patients receiving mechanical ventilation: a randomized clinical trial. JAMA. 2019;321(22):2175-2182.
2. Mancebo J, Goligher E, Brochard L. Spontaneous breathing trials and successful extubation [editorial]. JAMA. 2019;322(17):1716-1717.
3. Comparison of T-piece and pressure support ventilation as spontaneous breathing trials in critically ill patients: a systematic review and meta-analysis. J Intensive Care. 2020;8:12.
4. Thille AW, Gacouin A, Coudroy R, et al. Pressure-support ventilation vs T-piece during spontaneous breathing trials before extubation among patients at high risk of extubation failure: a post-hoc analysis. Chest/J Crit Care. 2020.
5. Schmidt GA, Girard TD, Kress JP, et al; ATS/CHEST Ad Hoc Committee on Liberation From Mechanical Ventilation in Adults. Official executive summary of an American Thoracic Society/American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Am J Respir Crit Care Med. 2017;195:115-119.
6. Santos Pellegrini JA, Boniatti MM, Boniatti VC, et al. Pressure-support ventilation or T-piece spontaneous breathing trials for patients with chronic obstructive pulmonary disease — a randomized controlled trial. PLoS One. 2018;13:e0202404.
7. Thille AW, Coudroy R, Gacouin A, et al. T-piece versus pressure-support ventilation for spontaneous breathing trials before extubation in patients at high risk of reintubation: protocol for a multicentre, randomised controlled trial (TIP-EX). BMJ Open. 2020;10(11):e042619.
8. The Washington Manual of Critical Care, 4th ed. 2025 — ventilator liberation chapter.
9. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant weaning content.